Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19560079 | 0.91 | MAPK14 (0.52) | MAPK14DRD4ALDH1A1TP53CYP3A4 | |
| SCHEMBL7594473 | 0.89 | MAPK14 (0.48) | MAPK14FFAR4 | |
| SCHEMBL10387224 | 0.87 | MAPK14 (0.50) | MAPK14DRD4TP53TSHR | |
| SCHEMBL9833970 | 0.87 | MAPK14 (0.50) | MAPK14DRD4TP53TSHR | |
| SCHEMBL9833964 | 0.87 | MAPK14 (0.50) | MAPK14DRD4TP53TSHR | |
| SCHEMBL8994562 | 0.86 | TDP1 (0.53) | MAPK14 | |
| SCHEMBL9774729 | 0.83 | MAPK14 (0.53) | MAPK14DRD4ALDH1A1TP53TSHR | |
| SCHEMBL9774733 | 0.83 | MAPK14 (0.53) | MAPK14DRD4ALDH1A1TP53TSHR | |
| SCHEMBL22710272 | 0.80 | TDP1 (0.59) | MAPK14ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL12661468 | 0.77 | ALDH1A1 (0.54) | MAPK14DRD4ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040027-A1 | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | KARRER FRIEDRICH (CH) | 2002-04-04 | — | — | US | disclosed |
| EP-0933998-A1 | METHOD FOR THE PREVENTION OF THE REINFESTATION OF WARM-BLOODED ANIMALS BY ECTOPARASITES | Novartis AG (CH) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998016107-A1 | METHOD FOR THE PREVENTION OF THE REINFESTATION OF WARM-BLOODED ANIMALS BY ECTOPARASITES | NOVARTIS AG (CH) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040027-A1 | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | SERPINC1, RXFP3, SERPINA3 | MAPK14 3197/4885DRD4 2850/4885FFAR4 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.